Showing results (551-560 of 637) with videos related to

Sort By:
Pageof 64
The Journal of Biological Chemistry|July 7, 2012
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry stepsViet Loan Dao Thi, Christelle Granier, Mirjam B Zeisel, et al.
The Journal of Gene Medicine|April 15, 2000
Myocardial injury-induced fibroblast proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivoJ Byun, J E Huh, S J Park, et al.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|August 1, 1996
Hematopoiesis research in aplastic anaemia induced by accidental protracted radiationG Socié, K Medhi Sohrabi, E D Carosella, et al.
Cancer Discovery|September 13, 2017
Galectin-3, a Druggable Vulnerability for KRAS-Addicted CancersLaetitia Seguin, Maria F Camargo, Hiromi I Wettersten, et al.
The Journal of Biological Chemistry|May 6, 2006
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BIMarlène Dreux, Thomas Pietschmann, Christelle Granier, et al.
Journal of Thrombosis and Haemostasis : JTH|September 30, 2016
Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc<sup>-/-</sup> miceC Levy, F Fusil, F Amirache, et al.
The Journal of Biological Chemistry|July 31, 2015
Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse ModelSara Calattini, Floriane Fusil, Jimmy Mancip, et al.
Retrovirology|November 13, 2014
ADAR1 enhances HTLV-1 and HTLV-2 replication through inhibition of PKR activityAnne Cachat, Sandrine Alais, Sébastien Alain Chevalier, et al.
Gene Therapy|November 18, 2000
Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cellsD Nègre, P E Mangeot, G Duisit, et al.
Bone Marrow Transplantation|June 19, 1998
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's diseaseV Ribrag, F Nasr, J H Bouhris, et al.
Pageof 64